Table 2 Evaluation of BASFI, BASDAI, HAQs and DAS-28 of the two groups of patients with psoriatic arthritis, at different times of follow-up
Outcomes | FT (N = 20) | RE (N = 21) | p-value between-group (GLM) |
|---|---|---|---|
BASFI | p = 0.919 | ||
T0 | 4.2 (2.6) | 3.8 (2.4) | |
T6 | 3.3 (2.5)# | 3.3 (2.3)# | |
T12 | 2.8 (2.1)# | 3.3 (2.1)# | |
Intragroup (GLM) | *p = 0.007 | *p = 0.007 | |
BASDAI | p = 0.700 | ||
T0 | 5.2 (2.4) | 4.7 (2.2) | |
T6 | 3.3 (2.4)# | 3.8 (2.2)# | |
T12 | 3.2 (2.0)# | 3.8 (2.2)# | |
Intragroup (GLM) | *p < 0.001 | *p < 0.001 | |
HAQs | p = 0.932 | ||
T0 | 0.71 (0.43) | 0.66 (0.4) | |
T6 | 0.52 (0.41)# | 0.52 (0.4)# | |
T12 | 0.44 (0.42)# | 0.52 (0.4)# | |
Intragroup (GLM) | *p < 0.001 | *p < 0.001 | |
DAS-28 | p = 0.106 | ||
T0 | 4.0 (1.3) | 4.2 (1.1) | |
T6 | 3.0 (1.1)# | 3.6 (0.9)# | |
T12 | 3.0 (1.2)# | 3.8 (1.1)# | |
Intragroup (GLM) | *p < 0.001 | *p < 0.001 |